Authors
Latest:
Empowering Ovarian Cancer Patients: How to Educate and Support Those Starting ADC TherapyCounseling Patients on ADC Side Effects Patient education is a cornerstone of successful ADC treatment. When introducing ADCs, providers focus on transparency—discussing the most common side effects upfront and reinforcing that many are reversible with dose holds or modifications. Eye toxicities and lung-related side effects like pneumonitis often cause anxiety. Clear communication and reassurance that these can be managed effectively help build trust. Educational materials and follow-up calls ensure patients feel supported and informed. Ultimately, the goal is to empower patients to report symptoms early and remain engaged in their care. ADC therapy offers significant clinical benefit, and with proactive management, patients can achieve extended survival and maintain their quality of life throughout treatment.
Latest:
Effective Communication is Necessary for Pathologists to Make Accurate DiagnosesIn community settings, offices may have to send pathology specimens to reference labs, and it may be difficult to maintain effective communication.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate CancerThis is the case of a man, aged 56 years, who presented with urinary intermittency, frequency, urgency, and dysuria 5 months after undergoing focal laser ablation (FLA) of Gleason 3 + 4 = 7 prostate cancer (PC).
Latest:
Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal DiseaseThis retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.
Latest:
IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMMThe panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.
Latest:
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and TherapyKhaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AMLMultiple mutations and gene alterations make targeted therapy development more difficult for patients with AML, according to Amir Fathi, MD.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
